Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.43 |
| ▸ | GNA15 | P30679 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577149 | 0.94 | FFAR1 (0.48) | PTGESALOX5FFAR1AKR1B1FFAR4 | |
| SCHEMBL3589161 | 0.90 | HSD17B2 (0.45) | HSD17B2SLC2A1SLC2A4TDP1PTGES | |
| SCHEMBL3588588 | 0.88 | ALOX5 (0.52) | PTGESALOX5FFAR1NR4A2LTC4S | |
| SCHEMBL3589183 | 0.86 | PARP15 (0.53) | PTGESALOX5FFAR1FFAR4MRGPRX4 | |
| SCHEMBL3584344 | 0.86 | MAOB (0.53) | PTGESALOX5NR4A2 | |
| SCHEMBL3591193 | 0.82 | ADAMTS4 (0.41) | HSD17B2PTGES | |
| SCHEMBL3578758 | 0.82 | PTGES (0.51) | HSD17B2TDP1PTGESALOX5FFAR1 | |
| SCHEMBL3588841 | 0.82 | FFAR1 (0.47) | PTGESALOX5FFAR1FFAR4PTGER4 | |
| SCHEMBL2247496 | 0.81 | HSD17B2 (0.40) | HSD17B2SLC2A1SLC2A4TDP1PTGES | |
| SCHEMBL2250531 | 0.81 | HSD17B2 (0.43) | HSD17B2SLC2A1SLC2A4TDP1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | claimed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | HSD17B2 2502/4885SLC2A1 880/4885SLC2A4 1253/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | HSD17B2 2502/4885SLC2A1 880/4885SLC2A4 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.